Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marinus Pharmaceuticals, a developer of specialty therapeutics to treat neurological and psychiatric disorders, has completed its Phase II clinical trial of ganaxolone for the treatment of infantile spasms. The company also completed enrollment for its Phase II clinical trial of ganaxolone for the treatment of adult partial complex seizures.
Subscribe to our email newsletter
Previous Phase I and proof of concept studies of ganaxolone have demonstrated safety and efficacy in refractive epilepsy. The ganaxolone program currently consists of four clinical studies, one infantile spasms and one adult partial seizure study as well as open label extensions for each study.
John Krayacich, CEO of Marinus, said: “Completion of the infantile spasms study and the completion of recruitment in the adult partial seizure trial are significant milestones for the ganaxolone program.
“We are anxious to review the unblinded data in the infantile spasms study and hope to present the data to the medical community early in 2009. We anticipate the data in the adult study to be available in the first half of 2009 and to present the data in the second half of 2009.”